Cilostazol reduces PAC-1 expression on platelets in ischemic stroke

Journal of Clinical Neurology (Korea)

Volumn 4, Issue 4, 2008, Pages 148-152

  Lee, Su Yun ^a   Kang, Myong Jin ^b   Cha, Jae Kwan ^a,b  

^a Department of Preventive Medicine Internal Medicine   (South Korea)

^b Dong A University   (South Korea)

Author keywords

Acute ischemic stroke; Cilostazol

Indexed keywords

EID: 78249247223     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2008.4.4.148     Document Type: Article

References (25)

1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340:115-126.
2. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-1249.
3. Pereira AC, Brown MM. Aspirin or heparin in acute stroke. Br Med Bull 2000;56:413-421.
4. Markus HS. Current treatments in neurology: stroke. J Neurol 2005; 252:260-267.
5. Norris JW. Antiplatelet agents in secondary prevention of stroke: a perspective. Stroke 2005;36:2034-2036.
6. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, et al. Cilos-tazol Prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilos-tazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782-786.
7. Goldstein LB, Jones MR, Matchar DB, Edwards LJ, Hoff J, Chilukuri V, et al. Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke 2001;32:1091-1098.
8. Leira EC, Chang KC, Davis PH, Clarke WR, Woolson RF, Hansen MD, et al. Can we predict early recurrence in acute stroke? Cerebro-vasc Dis 2004;18:139-144.
9. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62:569-573.
10. Cha JK, Jeong MH, Lee KM, Bae HR, Lim YJ, Park KW, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopi-dogrel. J Thromb Thrombolysis 2002;14:145-150.
11. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
12. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673.
13. Zambahari R, Kwok OH, Javier S, Mak KH, Piyamitr S, Tri Ho HQ, et al. Clinical use of clopidogrel in acute coronary syndrome. Int J Clin Pract 2007;61:473-481.
14. Bhatt DL, Topol EJ. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004;148:263-268.
15. Yamasaki Y, Kim YS, Kawamori R. Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). Cardiovasc Diabetol 2006;5:16.
16. Dalainas I. Cilostazol in the management of vascular disease. Int An-giol 2007;26:1-7.
17. Steinhubl SR, Moliterno DJ. The role of the platelet in the patho-genesis of atherothrombosis. Am J Cardiovasc Drugs 2005;5:399-408.
18. Hagberg IA, Lyberg T. Blood platelet activation evaluated by flow cy-tometry: optimised methods for clinical studies. Platelets 2000;11:137-150.
19. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
20. Pulcinelli FM, Riondino S, Celestini A, Pignatelli P, Trifirò E, Di Renzo L, et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005;3: 2784-2789.
21. Wong S, Appleberg M, Ward CM, Lewis DR. Aspirin resistance in cardiovascular disease: a review. Eur J Vasc Endovasc Surg 2004;27: 456-465.
22. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and athero-thrombotic disease. J Am Coll Cardiol 2005;46:986-993.
23. Nomura S, Inami N, Iwasaka T, Liu Y. Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets 2004;15:167-172.
24. Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke 2005;36:2289-2292.
25. May AE, Langer H, Seizer P, Bigalke B, Lindemann S, Gawaz M. Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin Thromb Hemost 2007;33:123-127.